TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04678089

Intervention type: DRUG
Intervention: Bortezomib
Description: Objective To observe the safety and efficacy of bortezomib related biomarkers. Including genes, metabolites, etc
Study: NCT02514642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-dose ticagrelor
Description: low-dose ticagrelor (22.5 mg twice daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of clopidogrel (75mg once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose ticagrelor
Description: low-dose ticagrelor (22.5 mg twice daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of clopidogrel (75mg once daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of low-dose ticagrelor (22.5 mg twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of low-dose ticagrelor (22.5 mg twice daily)
Study: NCT00777582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: Oral single dose formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: Oral single dose formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: Oral single dose formulation
Study: NCT01760317

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Midline vs Parasagittal Lumbar Epidural Steroid Injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Midline vs Parasagittal Lumbar Epidural Steroid Injection
Study: NCT02730312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb14045
Description: Administered IV weekly up to 8 weeks, with or without step-up dosing
Study: NCT01835041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02713685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subarachnoid block
Description: Subarachnoid block will be given using 2.5 ml of 0.5%Bupivacaine for lower limb anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined Femoral and Sciatic nerve block
Description: Femoral and Sciatic nerve blocks will be given using total 40 ml of 0.25%of Bupivacaine to anesthetise for lower limb surgery
Study: NCT00462917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pleiotropic info, in-person disclosure
Description: Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during an in-person disclosure session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AD-only info, in-person disclosure
Description: Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pleiotropic info, phone disclosure
Description: Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during a telephone disclosure session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AD-only info, phone disclosure
Description: Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session.
Study: NCT02744105

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina
Description: Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
Study: NCT02841501

Intervention type: GENETIC
Intervention: Analysis of genetic polymorphisms
Description: An analysis of the SNPs (single nucleotide polymorphism) of 25 candidate genes will be performed. This analysis will be completed by a genome wide association study.
Study: NCT03543982

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral probiotic product
Description: Once per day (QD), 28 days
Study: NCT02467140

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parietex ProGrib self-fixating mesh
Description: Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh.
Study: NCT02628574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX518 monotherapy
Description: comparison of different (ascending) doses of TRX518 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX518 with gemcitabine
Description: comparison of different (ascending) doses of TRX518 in combination with gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX518 with pembrolizumab
Description: comparison of different (ascending) doses of TRX518 in combination with pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX518 with nivolumab
Description: comparison of different (ascending) doses of TRX518 in combination with nivolumab
Study: NCT04864964

Intervention type: PROCEDURE
Group type: OTHER
Intervention: combined conventional and pulsed radiofrequency (CCPRF)
Description: Patients with trigeminal neuralgia who underwent combined conventional and pulsed radiofrequency (CCPRF) for treatment of pain.
Study: NCT04064099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-fitted sports mouthguard
Description: Pressure dual laminated technique will be used to fabricate the mouthguards. Ethylene-vinyl acetate (EVA) thermoplastic sheets of 3 mm in thickness with 125 mm diameter (Dentsply International Raintree Essix, Court East Sarasota, USA) will be used. Two 3 mm sheets pressure-laminated together should form an even thickness of 4 mm mouthguard. The design of the mouthguards takes into consideration of the following limits: (i) the labial borders of the mouthguard were extended to within 2 mm of the vestibular reflection, (ii) the palatal margins were trimmed to the cervical area of the palatal surface of the upper teeth, (iii) enclosing the maxillary teeth to the distal surface of the first molars.
Study: NCT04667611

Intervention type: BEHAVIORAL
Intervention: Psychosocial interventions
Description: Cognitive behavioural therapy (CBT) based individual and group intervention

Intervention type: BEHAVIORAL
Intervention: Psychosocial interventions
Description: Cognitive behavioural therapy (CBT) based individual and group intervention

Intervention type: BEHAVIORAL
Intervention: Psychosocial interventions
Description: Cognitive behavioural therapy (CBT) based individual and group intervention
Study: NCT03145376

Intervention type: DIAGNOSTIC_TEST
Intervention: geriatric assessment
Description: 1. Clinical evaluation and geriatric assessment with:~   1. CIRS: CIRS (Cumulative Illness Rating Scale)~  2. ADL (Activities of Daily Living);~  3. IADL (InstrumentalActivities of Daily Living);~  4. Mini Nutritional Assessment;~  5. Evaluation of quality of life (Short Form 36, SF-36).~2. Making a traditional 12-lead ECG.~3. A single lead electrocardiographic registration (DI, D II and D III) of 5 minutes baseline and 5 minutes with controlled breathing (15 breaths / min), using the Spectralink 2011 program, which allows us to identify and calculate the variables object of study;~4. transthoracic echocardiogram.
Study: NCT03425240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerve Stimulation
Description: Acute placement of electrodes on the pelvic plexus to apply electrostimulation during open radical prostatectomy.
Study: NCT00325351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (ZK 219477) + carboplatin
Description: Chemotherapy for recurrent ovarian cancer
Study: NCT01162109

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops.~A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Zinc sulfate
Description: A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops.~A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops.~A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis.
Study: NCT01069692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759A
Description: SBR759A 6g daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SBR759A
Description: Placebo Comparator 0g daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759A
Description: SBR759A 3g daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759A
Description: 9g daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759A
Description: 12g daily
Study: NCT01052220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BP education and BP self-regulation
Description: The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will be asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI will visit weekly with the intervention participants in the HD unit. to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Educative Nursing Intervention
Description: BP Education, BP, salt and fluid monitoring, BP goal-setting, and reinforcement
Study: NCT04447573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T
Description: Biological: BCMA CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
Study: NCT01196754

Intervention type: OTHER
Group type: OTHER
Intervention: sevoflurane
Study: NCT01921582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: * Weekly appointments with study psychiatrists for the first four weeks, and then biweekly appointments for the last eight weeks.~* Intervention will consist of medication as well as components of Med-Plus treatment (e.g., medication management, general support, and compliance enhancement strategies).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavior Therapy will include three phases:~* Phase 1 undertakes to eliminate binge episodes and introduce a 'regular' pattern of eating;~* Phase 2 aims to reduce food intake and restructure eating-related cognitions;~* Phase 3 focuses upon relapse prevention
Study: NCT01698606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary, family-centered lifestyle intervention with behavioral counseling
Description: Parent/caregiver education with skill training and practical activities revolving around healthy dietary choices, establishing an active versus a sedentary lifestyle, and behavioral aspects, while children will be engaged in active play.
Study: NCT02467140

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tack fixation
Description: Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh using tack fixation.
Study: NCT00880178

Intervention type: DRUG
Intervention: Simvastatin and Extended-Release niacin
Description: Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
Study: NCT01698606

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary, family-centered lifestyle intervention with behavioral counseling
Description: Parent/caregiver education with skill training and practical activities revolving around healthy dietary choices, establishing an active versus a sedentary lifestyle, and behavioral aspects, while children will be engaged in active play.
Study: NCT03892967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03559595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Prevent
Description: The Project Prevent intervention entails 1) a media campaign to raise PrEP awareness, 2) geographically targeted education initiatives with medical personnel to increase access to consumers, and 3) programming with AIDS service organizations to improve service delivery around PrEP.
Study: NCT03923062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chemicalpeeling
Description: Cleansing and degreasing the face with alcohol .~* The patients must be sitting at an angle of 45.~* A 2 × 2 cm cotton gauze will be used to apply TCA 20%.~* We will apply the acid from the midline to the right side of the forehead and under the right eye, covering the right cheek and perioral area.~* We then will wait for a few minutes and will observe the frost developing.~* The patient will be then allowed to wash her face.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chemicalpeeling
Description: Cleansing and degreasing the face with alcohol .~* The patients must be sitting at an angle of 45.~* A 2 × 2 cm cotton gauze will be used to apply TCA 20%.~* We will apply the acid from the midline to the right side of the forehead and under the right eye, covering the right cheek and perioral area.~* We then will wait for a few minutes and will observe the frost developing.~* The patient will be then allowed to wash her face.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryopeeling
Description: Cryopeeling will be performed by spraying the freezing substance(Liquid Nitrogen) on the face at 1-2cm distance and moving along the affected area until freezing appear.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: microneedling
Description: Tranexamic acid will be used in aconcentration of 4mg/ml ,1ml will be used fo half of the face.~* After gentle cleansing, topical analgesic cream will be applied over the area to be treated.~* The microneedles will be used, the skin will be stretched and microneedling will be carried out in vertical, horizontal, and both diagonal directions for about four to five times. Tranexamic acid, 0.5 to 1 ml (4 mg/mL), will be applied over this area, and the procedure will be repeated four to five times in the above-said directions
Study: NCT04189874

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Stool Testing
Description: Stools are tested using conventional culture techniques

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BioFire FilmArray Gastrointestinal Panel
Description: Molecular-based stool assay
Study: NCT01474291

Intervention type: BIOLOGICAL
Intervention: Tocilizumab
Description: Tocilizumab administered according to prescribing information and normal clinical practice.
Study: NCT02486458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride varnish
Description: Fluoride varnish containing 22,600 ppm F, as NaF, in a neutral base

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride varnish
Description: Fluoride varnish containing 22,600 ppm F, as NaF, in a neutral base

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.23% sodium fluoride acidic gel
Description: Fluoride gel containing 12,300 ppm F (as NaF) in an acidic pH (by addition of phosphoric acid)
Study: NCT01826305

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Formal Rehabilitation Therapy
Description: Patients that will be randomized to the formal rehabilitation therapy cohort will be prescribed formal therapy for twelve weeks with supervised exercises to regain knee strength and range of motion. Therapists will not be involved in the study design and therapists will not be informed that patients are participating in this study. The content, frequency, and duration of the rehabilitation program will be at the discretion of the treating therapist, consistent with usual practice.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Independent Exercise Cohort
Description: The patients who will be in the independent exercises cohort will be registered on www.careforpatients.com, an online rehabilitation resource that provides computer aided rehabilitative exercises. Patients will follow a prepared 12-week protocol of exercises to perform post-operatively to gradually regain their knee strength, flexion, extension, abduction, and adduction.
Study: NCT03781050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months~For adults: rapamycin, 2 mg a day, orally, for at least 6 months
Study: NCT03058861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play Nicely Program
Description: Play Nicely multimedia program and handbook that provides education about healthy discipline strategies.
Study: NCT00848302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: 30 patients will receive either 50, 100 or 500mg L-arginine supplementation infused via a end-hole catheter
Study: NCT01283061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zafirlukast
Description: Zafirlukast tablets 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zafirlukast
Description: Zafirlukast tablets 20 mg
Study: NCT03991455

Intervention type: DEVICE
Group type: OTHER
Intervention: Apyx device
Description: The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system.
Study: NCT02042742

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: punicalagin and hydroxytyrosol mixture
Description: Antioxidant Supplement (punicalagin and hydroxytyrosol mixture) During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control supplement (maltodextrin)
Description: During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
Study: NCT00690612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil
Description: 0.05, 0.2, 0.4 mg/kg, oral solution, single daily dose
Study: NCT04835142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double blind control period A140
Description: experiment arm： Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h) control arm: Drug Erbitux:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv) Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open single period A140
Description: Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)
Study: NCT00880178

Intervention type: DRUG
Intervention: Simvastatin
Description: Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
Study: NCT05071521

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Body Project: A Dissonance-Based Eating Disorder Prevention Intervention
Description: The Body Project is a a selective dissonance-based prevention program that targets women with body image concerns. It has been developed with University and similar populations in mind, making it appropriate to the current research.The Body Project is based on a protocol, and aims to create cognitive dissonance that encourages participants to reduce pursuit of the thin-ideal. It involves the use of a scripted manual, covering four interactive weekly sessions. These involve role play, behavioural, verbal and written exercises.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: The Body Project: A Dissonance-Based Eating Disorder Prevention Intervention
Description: The Body Project is a a selective dissonance-based prevention program that targets women with body image concerns. It has been developed with University and similar populations in mind, making it appropriate to the current research.The Body Project is based on a protocol, and aims to create cognitive dissonance that encourages participants to reduce pursuit of the thin-ideal. It involves the use of a scripted manual, covering four interactive weekly sessions. These involve role play, behavioural, verbal and written exercises.